Trial site
Darlinghurst
Darlinghurst, New South Wales 2010, AustraliaNot linked to an institution yet
- 14running trials
- 1closed trial
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 1/24 trials
- Phase 13 trials
- Phase 33 trials
- Phase 22 trials
- Phase 42 trials
- Phase 2/31 trial
- Status
- Active, not recruiting8 trials
- Recruiting6 trials
- Completed1 trial
- Lead sponsor
- Novartis Pharmaceuticals15 trials
Running trials
Recruiting
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
NCT07801508· Phase 1· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
NCT07660055· Phase 1· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670· Phase 2/3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
NCT06675864· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995· Phase 1/2· Novartis Pharmaceuticals· Source
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
NCT05983198· Phase 1· Novartis Pharmaceuticals· Source
Active, not recruiting
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829· Phase 4· Novartis Pharmaceuticals· Source
Active, not recruiting
CINC424A2X01B Rollover Protocol
NCT02386800· Phase 4· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error